GSK_ Annual_Report_2021-22

Our focus brands GENERAL MEDICINES • Multivitamin with zinc combination, including 4 essential B-vitamins and trace elements of chromium, zinc and selenium • Ranked No. 7 in the category* • Prescribed by more than 30,000 HCPs Cobadex CZS • Indicated for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type B • Powder and suspension for injection in intramuscular use • Ranked No. 1 in the segment* • Trusted among paediatricians • Market leader in DTP Hexavalent vaccine category* with over two decades of market presence • Registered in over 90 countries • Indicated for active immunisation of infants against pneumococcal diseases and acute otitis media caused by Streptococcus pneumoniae and Non-Typeable Haemophilus influenzae • Injectable suspension for intramuscular use • Ranked No. 2 in the segment* • Trusted for over 10 years in more than 130 countries • More than 20 crore babies protected against pneumococcal diseases and AOM caused by S. Pneumoniae and NTHi Infanrix Hexa Synflorix • Supacef is a bactericidal cephalosporin antibiotic • Indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria • Ranked No. 1 in the category* Supacef • Indicated for active immunisation against disease caused by Hepatitis A virus (HAV) from 1+ year of age • Injectable suspension for intramuscular use • Ranked No. 2 in the segment* • Rapid seroconversion and at least 50 years of long-term protection against Hepatitis A • Most widely studied Hepatitis A vaccine registered in over 90 countries • Indicated for active immunisation from 2 years of age to prevent invasive meningococcal disease caused by Neisseria Meningitidis groups A, C, W-135 and Y • Powder and solution for injection in intramuscular use • Over 10 years of global experience and approved in the US and the EU countries Havrix Menveo VACCINES *Source: IQVIA MAT March 2022 6 GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22